Why is small-batch production increasing in biologics?

Biologic products are increasingly personalized, high-value, and produced in smaller volumes. Many biotech companies also prefer lower initial production risk before scaling up commercially.

Oversized production lines can create unnecessary operational costs for early-stage biologics.

📩 Message me here or email me at ([email protected])

FAQ

• Compact flexible systems
• RTU nested filling
• Small-batch optimized filling accuracy
• Low product loss design
• Easy future scale-up